Does interferon- improve pulmonary function in idiopathic pulmonary fibrosis?
نویسندگان
چکیده
منابع مشابه
Does interferon-c improve pulmonary function in idiopathic pulmonary fibrosis?
Does interferon-c improve pulmonary function in idiopathic pulmonary fibrosis? A. Prasse, K-M.Müller, C. Kurz, H. Hamm, J.C. Virchow Jr. #ERS Journals Ltd 2003. ABSTRACT: Idiopathic pulmonary fibrosis (IPF) is a disease with progressive and devastating deterioration of lung function and a fatal prognosis, despite aggressive therapeutic attempts, which, in the majority of cases are futile. Recen...
متن کاملPulmonary Rehabilitation in Idiopathic Pulmonary Fibrosis: A Chance for a Multidisciplinary Treatment Approach
Background and Objectives: Idiopathic pulmonary fibrosis (IPF) is characterized by progressively worsening lung function, ventilation capacity, dyspnea, and finally reduced exercise intolerance. All of these have a significant negative impact on functional capacity and quality of life. In this study, we aim to evaluate the effects of pulmonary rehabilitation (PR) in IPF and assess the predictor...
متن کاملPediatric Idiopathic Pulmonary Fibrosis: A Case Series report
Khalilzadeh S1, Baghaei N2, Bolorsaz MR1, Masjedi MR3 1. Associate professor, Department of pediatrics, Education, research and treatment center of tuberculosis and long diseases, Shahid Beheshti University of medical sciences 2. Assistant professor, Department of pediatrics, Education, research and treatment center of tuberculosis and long diseases, Shahid Beheshti University of medical s...
متن کاملREPORT OF FOUR CASES OF FAMILIAL IDIOPATHIC PULMONARY FIBROSIS
A 25 year old male and his 46 year old aunt presented with shortness of breath and a dramatic response to steroids. The other two patients are sisters with more advanced disease. One of these responded partially to steroids, while the other died within 4 months of treatment. The genetic basis and pathogenesis are discussed.
متن کاملPulmonary hypertension in idiopathic pulmonary fibrosis.
Idiopathic pulmonary fibrosis (IPF) is an untreatable diffuse parenchymal lung disease with a median survival of < 3 years. Pulmonary hypertension (PH) is frequently seen in patients with IPF and is commonly attributed to hypoxic vasoconstriction and capillary destruction. Pathology findings include endothelial proliferation and medial hypertrophy that exceed those expected in the setting of hy...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Respiratory Journal
سال: 2003
ISSN: 0903-1936,1399-3003
DOI: 10.1183/09031936.03.00091802